Life sciences regulatory & compliance partner and chair Greg Levine, counsel Beth Weinman and associate Joshua Oyster (all of Washington, D.C.) co-authored a Law360 article that examines the likely impact, both during and after the COVID-19 pandemic, of a recent U.S. Department of Health and Human Services announcement preventing FDA from insisting on premarket review for laboratory-developed tests absent notice and comment rulemaking.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find our more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.